4basebio (LON:4BB) Trading Up 4.8% – Time to Buy?

Shares of 4basebio PLC (LON:4BB) rose 4.8% during mid-day trading on Wednesday . The stock traded as high as GBX 550 and last traded at GBX 550. Approximately 311 shares were traded during trading, a decline of 80% from the average daily volume of 1,576 shares. The stock had previously closed at GBX 525.

Analyst Upgrades and Downgrades

Separately, Royal Bank Of Canada cut their price objective on 4basebio from GBX 1,600 to GBX 1,400 and set an “outperform” rating for the company in a report on Monday, June 15th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of GBX 1,400.

4basebio Stock Performance

The company’s 50-day moving average price is GBX 506.51 and its two-hundred day moving average price is GBX 534.89. The company has a market cap of £85.17 million, a P/E ratio of -5.05 and a beta of 1.09. The company has a current ratio of 2.73, a quick ratio of 3.52 and a debt-to-equity ratio of 201.47.

4basebio (LON:4BB) last released its earnings results on Wednesday, May 20th. The company reported GBX (1.09) EPS for the quarter. The company had revenue of GBX 169 million for the quarter. As a group, equities analysts forecast that 4basebio PLC will post -3.43 earnings per share for the current year.

Insider Activity

In related news, insider Amy Walker purchased 1,863 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of GBX 509 per share, with a total value of £9,482.67. Corporate insiders own 12.08% of the company’s stock.

About 4basebio

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.